Business Context and Reporting Period
Unicycive Therapeutics, Inc. (UNCY) filed a Form 8-K on November 11, 2024, reporting a significant regulatory milestone. The company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material event reported is the acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) by the U.S. Food and Drug Administration (FDA). The FDA has established a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the NDA acceptance and the PDUFA date. The filing does not provide updated financial guidance, discuss specific risks, or detail contingencies beyond the standard regulatory review process implied by the NDA submission.
Investor Verification Checklist
- Verify the status of the NDA for Oxylanthanum Carbonate (OLC) on the FDA website.
- Confirm the PDUFA target action date of June 28, 2025, for potential approval or complete response letter.
- Review the full text of the press release (Exhibit 99.1) for additional clinical or commercial details not summarized here.
- Check subsequent filings for any updates on the regulatory review timeline or potential delays.